在多发性硬化症的治疗中,脂质体辅助药物输送
Giuliana Greco1,2, Maria Grazia Sarpietro2,3
1Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Molecules (Basel, Switzerland)
|October 16, 2024
概括
脂质体提供了一个有前途的纳米载体战略,用于输送治疗多发性硬化症 (MS) 的药物. 这种方法旨在提高药物的疗效,并减少与MS常规治疗相关的副作用.
科学领域:
- 神经免疫学 神经免疫学
- 纳米医学是一种纳米医学.
- 药物输送系统 药物输送系统
背景情况:
- 多发性硬化症 (MS) 是一种衰弱的免疫媒介脱髓化疾病,影响神经系统.
- 对于MS的传统疗法往往缺乏选择性,导致显著的全身副作用和毒性.
- 需要先进的治疗策略来有效管理多发性硬化.
研究的目的:
- 审查脂质体作为纳米载体的应用,用于多发性硬化症治疗中的药物活性输送.
- 提供与MS治疗相关的脂质体准备,表征和稳定性的概述.
- 分析现有的关于多发性硬化症脂质体药物输送的文献.
主要方法:
- 关于脂质体和多发性硬化症治疗的科学出版物的文献综述.
- 脂质体特征的分析,包括制备技术,表征方法和稳定性评估.
- 对详细介绍使用脂质体在多发性硬化症患者的向药物输送中的研究进行评估.
主要成果:
- 纳米载体,特别是脂质体,在MS治疗中显示出控制和向药物释放的潜力.
- 脂质体可以减轻与高治疗剂量,药物降解和全身副作用相关的问题.
- 该审查综合了关于用于MS治疗的脂质体配方的当前知识.
结论:
- 脂质体代表了一个可行的纳米载体系统,用于增强多发性硬化症治疗药物的输送.
- 这种方法提供了一种策略,通过尽量减少不良影响来改善治疗结果和患者的耐受性.
- 在脂质体药物输送方面进行进一步的研究和开发有望促进MS治疗的进展.
关键词:
这是BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB在EAE模型中,EAE模型是什么?药物输送是药物输送的过程.脂质体是一种脂质体.多发性硬化症多发性硬化症纳米载体的纳米载体
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
358
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
358
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
01:19Multiple Sclerosis l: Introduction
31
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31